Vir Biotechnology, Inc.
Clinical trials sponsored by Vir Biotechnology, Inc., explained in plain language.
A clinical-stage immunology company focused on infectious diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug duo takes on rare liver virus in head-to-head trial Results expected Nov 2026 (estimated)
- New drug combo aims to tackle stubborn hepatitis d Results expected Dec 2026 (estimated) 🚀 Make-or-break
- New drug duo aims to control hard-to-treat hepatitis delta Results expected Dec 2026 (estimated) 🚀 Make-or-break
-
New drug combo targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called VIR-5818, alone or combined with the immunotherapy pembrolizumab, in people with advanced HER2-expressing cancers that have not responded to standard treatments. The study will first find the safest dose, then expand to see if t…
Phase 1/2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New cancer drug VIR-5525 enters first human trials for EGFR-Positive tumors
Disease control Recruiting nowThis early-stage study tests a new drug called VIR-5525, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have a protein called EGFR. The main goals are to check safety and find the right dose. About 450 adults with tumors that cannot b…
Phase 1 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC